Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
Special Considerations
Kidney Problems:
- No dose adjustment typically needed
- Monitor renal function regularly
Liver Problems:
- Limited data available
- Use with caution in hepatic impairment
Elderly:
- No specific dose adjustments required
- Monitor for increased sensitivity to side effects
Children:
- Not studied in pediatric populations
- Not recommended for use under 18 years
Special Considerations
Kidney Problems
- No dose adjustment typically needed
- Monitor renal function regularly
Liver Problems
- Limited data available
- Use with caution in hepatic impairment
Elderly
- No specific dose adjustments required
- Monitor for increased sensitivity to side effects
Children
- Not studied in pediatric populations
- Not recommended for use under 18 years
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.